130 related articles for article (PubMed ID: 17441606)
1. Using clinical information in goal-oriented learning.
Gaweda AE; Muezzinoglu MK; Aronoff GR; Jacobs AA; Zurada JM; Brier ME
IEEE Eng Med Biol Mag; 2007; 26(2):27-36. PubMed ID: 17441606
[TBL] [Abstract][Full Text] [Related]
2. Simplification of an erythropoiesis model for design of anemia management protocols in end stage renal disease.
Nichols B; Shrestha RP; Horowitz J; Hollot CV; Germain MJ; Gaweda AE; Chait Y
Annu Int Conf IEEE Eng Med Biol Soc; 2011; 2011():83-6. PubMed ID: 22254256
[TBL] [Abstract][Full Text] [Related]
3. Model predictive control of erythropoietin administration in the anemia of ESRD.
Gaweda AE; Jacobs AA; Aronoff GR; Brier ME
Am J Kidney Dis; 2008 Jan; 51(1):71-9. PubMed ID: 18155535
[TBL] [Abstract][Full Text] [Related]
4. Optimization of anemia treatment in hemodialysis patients via reinforcement learning.
Escandell-Montero P; Chermisi M; Martínez-Martínez JM; Gómez-Sanchis J; Barbieri C; Soria-Olivas E; Mari F; Vila-Francés J; Stopper A; Gatti E; Martín-Guerrero JD
Artif Intell Med; 2014 Sep; 62(1):47-60. PubMed ID: 25091172
[TBL] [Abstract][Full Text] [Related]
5. Would artificial neural networks implemented in clinical wards help nephrologists in predicting epoetin responsiveness?
Gabutti L; Lötscher N; Bianda J; Marone C; Mombelli G; Burnier M
BMC Nephrol; 2006 Sep; 7():13. PubMed ID: 16981983
[TBL] [Abstract][Full Text] [Related]
6. Prediction of the hemoglobin level in hemodialysis patients using machine learning techniques.
Martínez-Martínez JM; Escandell-Montero P; Barbieri C; Soria-Olivas E; Mari F; Martínez-Sober M; Amato C; Serrano López AJ; Bassi M; Magdalena-Benedito R; Stopper A; Martín-Guerrero JD; Gatti E
Comput Methods Programs Biomed; 2014 Nov; 117(2):208-17. PubMed ID: 25070755
[TBL] [Abstract][Full Text] [Related]
7. Individualization of pharmacological anemia management using reinforcement learning.
Gaweda AE; Muezzinoglu MK; Aronoff GR; Jacobs AA; Zurada JM; Brier ME
Neural Netw; 2005; 18(5-6):826-34. PubMed ID: 16109475
[TBL] [Abstract][Full Text] [Related]
8. Control-relevant erythropoiesis modeling in end-stage renal disease.
Chait Y; Horowitz J; Nichols B; Shrestha RP; Hollot CV; Germain MJ
IEEE Trans Biomed Eng; 2014 Mar; 61(3):658-64. PubMed ID: 24235247
[TBL] [Abstract][Full Text] [Related]
9. Protocolized anemia management with erythropoietin in hemodialysis patients: a randomized controlled trial.
Brimble KS; Rabbat CG; McKenna P; Lambert K; Carlisle EJ
J Am Soc Nephrol; 2003 Oct; 14(10):2654-61. PubMed ID: 14514745
[TBL] [Abstract][Full Text] [Related]
10. An international observational study suggests that artificial intelligence for clinical decision support optimizes anemia management in hemodialysis patients.
Barbieri C; Molina M; Ponce P; Tothova M; Cattinelli I; Ion Titapiccolo J; Mari F; Amato C; Leipold F; Wehmeyer W; Stuard S; Stopper A; Canaud B
Kidney Int; 2016 Aug; 90(2):422-429. PubMed ID: 27262365
[TBL] [Abstract][Full Text] [Related]
11. Drug delivery optimization through Bayesian networks: an application to erythropoietin therapy in uremic anemia.
Bellazzi R
Comput Biomed Res; 1993 Jun; 26(3):274-93. PubMed ID: 8325006
[TBL] [Abstract][Full Text] [Related]
12. Treating renal anaemia with recombinant human erythropoietin: practical guidelines and a clinical algorithm.
Macdougall IC; Hutton RD; Cavill I; Coles GA; Williams JD
BMJ; 1990 Mar; 300(6725):655-9. PubMed ID: 2322705
[TBL] [Abstract][Full Text] [Related]
13. Erythropoietin and the anemia of chronic diseases.
De Marchi S; Pirisi M; Ferraccioli GF
Clin Exp Rheumatol; 1993; 11(4):429-44. PubMed ID: 8403591
[TBL] [Abstract][Full Text] [Related]
14. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients.
Vanrenterghem Y; Bárány P; Mann JF; Kerr PG; Wilson J; Baker NF; Gray SJ;
Kidney Int; 2002 Dec; 62(6):2167-75. PubMed ID: 12427142
[TBL] [Abstract][Full Text] [Related]
15. Use of neural networks for dosage individualisation of erythropoietin in patients with secondary anemia to chronic renal failure.
Martín Guerrero JD; Olivas ES; Valls GC; Serrano López AJ; Pérez Ruixo JJ; Torres NV
Comput Biol Med; 2003 Jul; 33(4):361-73. PubMed ID: 12791408
[TBL] [Abstract][Full Text] [Related]
16. Anemia of renal failure. Use of erythropoietin.
Humphries JE
Med Clin North Am; 1992 May; 76(3):711-25. PubMed ID: 1578966
[TBL] [Abstract][Full Text] [Related]
17. A novel evolutionary drug scheduling model in cancer chemotherapy.
Liang Y; Leung KS; Mok TS
IEEE Trans Inf Technol Biomed; 2006 Apr; 10(2):237-45. PubMed ID: 16617612
[TBL] [Abstract][Full Text] [Related]
18. Once weekly versus twice weekly subcutaneous administration of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis.
Lui SF; Law CB; Ting SM; Li P; Lai KN
Clin Nephrol; 1991 Nov; 36(5):246-51. PubMed ID: 1752075
[TBL] [Abstract][Full Text] [Related]
19. Assessment of erythropoietin for treatment of anemia in chronic kidney failure- ESRD patients.
Srinivasan R; Fredy IC; Chandrashekar S; Saravanan J; Mohanta GP; Manna PK
Biomed Pharmacother; 2016 Aug; 82():44-8. PubMed ID: 27470337
[TBL] [Abstract][Full Text] [Related]
20. How to design an anemia management protocol.
Senger JM; Trenkle JA; St John WD
ANNA J; 1998 Apr; 25(2):235-40. PubMed ID: 9801503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
